KR20100006895A - A composition comprising a dried powder of saury(coloabis saira) fraction or the extract thereof for preventing and treating oxidation related diseases - Google Patents

Abstract

PURPOSE: A composition containing pacific saury-dried fraction or its extract is provided to reduce oxygen free radical and malodialdehyde(MDA) and ensure SOD(superoxide dismutase) activity. CONSTITUTION: A pharmaceutical composition for preventing and treating oxidation-related diseases contains pacific saury fraction dried powder or its extract as an active ingredient. The pacific saury fraction dried powder is obtained by: washing the pacific saury, removing foreign material and salt; cutting the pacific saury to intestines, whole body, bone, cartilage, skin, muscle, eye and gills; and performing vacuum-drying or light drying of the fractions. The extract of the pacific saury fraction is obtained by grinding or pulverizing the fractions and extracting with water, alcohol or spirit. The oxidation-related diseases is cancer, diabetes, hepatitis, gastritis, nephritis, carditis, rheumatoid arthritis, heart disease, AIDS, cataract or dermatome.

Description

A composition comprising a dried powder of Saury (Coloabis saira) fraction or the extract describes for preventing and treating oxidation related diseases}

The present invention relates to a composition for preventing and treating oxidation-related diseases containing saury fraction dry powder or extract thereof as an active ingredient.

[Reference 1] Moini, H. et al., Antioxidant and prooxidant activities of alpha-lipoic acid and dihydrolipoic acid, Toxicology And Applied Pharmacology , 182 , pp. 84-90, 2002

Merte, O., Nutritional modification of cardiovascular disease risk, International Congress Serise , 1229 , pp. 109-114, 2002

Noguchi, N. et al., Dynamics of the oxidation of low density lipoprotein induced by free radicals, Biochem . Biophys . Res . Com , 213 , pp.360-366, 1995

Yan, LJ et al., Ginko biloba extract (EGb 761) protects human low density lipoproteins against oxidative modification mediated by copper, Biochem . Biophysics . Acta , 1168 , pp. 348-357, 1995

[5] Jeong, J. et al., Effects of Ligularia fischeri extracts on oxidation of low density lipoprotein, Korean J. Food Sci . Technol , 30 , pp. 1214-1221

[6] Lee, MJ et al., Antioxidative effects of Korean bamboo trees, Wang-dae, Som-dae, Maengjong-juk, Jolit-dae and O-juk, Korean J. Food Sci . Technol , 36 , pp. 1226-1232, 2003

Park, CO et al., Antioxidant activity of daidzin and puerarin toward oxidation of human low density lipoprotein, J. Korean Soc . Food Sci . Nutr . 26 , pp. 25-31, 1997

Park, CO et al., Antioxidant activity of green tea extracts toward human low density lipoprotein, Korean J. Food Sci . Technol , 28 , pp. 850-858, 1996

[Reference 9] Yag, KS et al., Effect of Taraxacum Nakai on low density lipoprotein oxidation, Korean J. Pharmacogn , 27 , pp. 267-273, 1996

[Ref 10] Lee Yeon-sil, et al., Effects of Seaweed Extracts of Moxibustion on Lipid Metabolism, Journal of Biochemistry, 35 (2) , pp.143-146, 2004

[11] Frings, CS et al, A colorimetric method for determination of total serum lipids based on the sulfophosphovanillin reaction, Am . J. Clin . Path . , 53 , pp.89-92, 1970

12, Chen, PS et al., Micro determination of phosphorus. Anal . Chem . , 28 , pp.1756-1760, 1956

12. McGowan, MW et al., A peroxidase-coupled method for the colorimetric determination of serum triglycerides, Clin . Chem . , 29 , pp.538-542, 1983

[13] Yagi, K. Lipid peroxides and human diseases. Chemistry and Physics of Lipids , 45 , pp. 337-342, 1987)

Kobatake, Y. et al., Influence of fish consumption on serum lipid and lipid peroxide concentrations in mide aged subjects. J. Japan Soc . Nutr . & Food Sci ., 40 , pp . 103-110, 1987

Oyanagui, Y. Reevaluation of assay methods and establishment of kit for superoxide dismutase activity. Anal . Biochem ., 42 , pp . 290-295, 1984

Recently, as economic interest and increasing national income increase interest in healthy life, researches are being actively conducted to find functional food and pharmaceutical materials derived from natural products that can prevent and treat diseases. It is attracting attention as a biologically active resource containing mutants, anticancer agents, and the like. Antioxidants eliminate reactive oxygen species (ROS) or reactive nitrogen species (RNS) that attack polyunsaturated fatty acids on cell membranes, causing lipid peroxidation. They are free radicals when they are not normally eliminated in vivo. The oxidative and nitrosative stresses of these tissues affect cell membranes, decrease enzyme activity, damage DNA and produce mutants in various tissues, and can cause cancer, atherosclerosis, inflammatory reactions, arthritis, It causes chronic degenerative diseases such as Alzheimer's disease, cataracts, asthma and ischemia (Moini, H. et al., Antioxidant and prooxidant activities of alpha-lipoic acid and dihydrolipoic acid, Toxicology And Applied Pharmacology, 182 , pp. 84- 90, 2002).

In particular, circulatory disease is the leading cause of death in the United States and Western Europe as the number one cause of death. In Korea, as the diet becomes westernized, blood circulation system diseases such as cerebrovascular diseases such as myocardial infarction and heart attack, stroke and peripheral blood system diseases are increasing day by day (Merte, O., Nutritional modification of cardiovascular disease risk, International Congress Serise , 1229 , pp. 109-114, 2002).

In order to prevent and treat oxidation-related diseases, antioxidants are needed. BHT, BHA, and probucol are widely used as antioxidants, but chemical synthetic products have been reported to inhibit the activity of bioenzymes and cause mutant cancers. Therefore, most antioxidants are not toxic to humans. Restrictions on use.

On the other hand, the α-tocopherol (α-tocopherol) and vitamin (vitamin) C, which is used as a natural antioxidant has a disadvantage that the antioxidant effect is relatively low and relatively expensive compared to the synthetic antioxidant. In addition, β-carotene, α-carotene, α-carotene, lycopene, retinoids and ubiquinol, most of which are known to be present in plants and polyphenols (polyphenol), flavonoids and derivatives thereof have been reported to have strong antioxidant activity (Noguchi, N. et al., Dynamics of the oxidation of low density lipoprotein induced by free radicals, Biochem . Biophys . Res . Com , 213 , pp. 360-366, 1995).

Therefore, there is an urgent need for the development of a composition for the prevention and treatment of diseases related to oxidation using natural antioxidants, which are excellent in antioxidant capacity, harmless to the human body and economical.

To report on the antioxidant studies so far Ginkgo biloba (Yan, LJ et al., Ginko biloba extract (EGb 761) protects human low density lipoproteins against oxidative modification mediated by copper, Biochem. Biophysics. Acta, 1168, pp.348 -357, 1995), Goong, J. et al., Effects of Ligularia fischeri extracts on oxidation of low density lipoprotein, Korean J. Food Sci . Technol , 30 , pp. 1214-1221, 1998), Bamboo (Lee, MJ et al., Antioxidative effects of Korean bamboo trees, Wang-dae, Som-dae, Maengjong-juk, Jolit-dae and O-juk, Korean J. Food Sci . Technol , 36 , pp.1226-1232, 2003) Antioxidant Effect of Extracts, Park, CO et al., Antioxidant activity of daidzin and puerarin toward oxidation of human low density lipoprotein, J. Korean Soc . Food Sci . Nutr . 26 , pp. 25-31, 1997), Green Tea (Park, CO et al., Antioxidant activity of green tea extracts toward human low density lipoprotein, Korean J. Food Sci . Technol , 28 , pp. 850-858, 1996), Dandelion (Yag, KS et al., Effect of Taraxacum Nakai on low density lipoprotein oxidation, Korean J. Pharmacogn , 27 , pp.267-273, 1996) Etc.

However, the application of antioxidant treatments is ridiculously insufficient. Therefore, there is an urgent need for the development of a composition for the prevention and treatment of diseases caused by oxidation-related diseases using natural products having excellent therapeutic effects and harmless to the human body.

Thus, the present inventors fractionated each part without using pollution-causing saury, an organic solvent extraction operation, and discarding part using saury, which is easily available in Korea, which is a three-sided sea, oral administration of saury fraction dry powder or extract thereof to hyperlipidemic rats The present invention was completed by confirming the antioxidative effect of lipid peroxide and active oxygen reduction and SOD (superoxide dismutase) activity.

In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing and treating oxidation-related diseases containing saury fraction dry powder or its extract as an active ingredient.

The present invention also provides a dietary supplement for the prevention and improvement of oxidation-related diseases containing saury fraction dry powder or its extract as an active ingredient.

The saury fraction as defined herein comprises at least one selected from the group consisting of the entire torso, flesh, gut, head, fin, bone, tail, cartilage, shell, muscle, eye, and gill of the saury, preferably the entire torso, And fractionate from at least one selected site from the group consisting of flesh, gut, head, fin, bone and tail, more preferably the entire torso or flesh.

Oxidation-related diseases as defined herein are at least one disease selected from the group consisting of cancer, diabetes, hepatitis, gastritis, nephritis, heartitis, rheumatoid arthritis, heart disease, acquired immunodeficiency syndrome, cataracts and skin tumors, preferably nephritis And cardiac disease.

The saury fraction dry powder or the pharmaceutical composition of the extract can be used in 0.1 to 50% by weight based on the total weight.

Hereinafter, the present invention will be described in detail.

Saury fraction dry powder or extract thereof of the present invention can be obtained by the following process.

The saury fraction dry powder of the present invention comprises a first treatment step of washing saury harvested in areas such as the East Sea coast after removing foreign matter and salt; A second step of obtaining each fraction through a process of dividing the saury into fractions such as whole body, flesh, intestine, head, fin, bone, tail, cartilage, shell, muscle, eyes and gill; The mackerel fraction dry powder of the present invention can be obtained through a manufacturing process including a third step of performing each drying method of the fractions, such as vacuum freeze drying and sun drying;

Saury fraction extract of the present invention is well known in the art using the extraction method to obtain each extract of the second step of the process by compression, grinding or blender and / or extraction solvent harmless to the human body, such as water, alcohol, alcohol, etc. Extraction method, for example, by adding the fraction in water for about 12 to 48 hours, preferably 20 to 40 hours, after heating at 60 ℃ to 150 ℃, preferably 80 ℃ to 120 ℃, the residue The saury fraction extract of the present invention may be obtained through a manufacturing process including a third step of filtering each extract with a filter paper after further performing a process of obtaining an extract obtained through the removing process.

The present invention provides a pharmaceutical composition for preventing and treating oxidation-related diseases containing saury fraction dry powder obtained by the above manufacturing process or its extract as an active ingredient.

The pharmaceutical compositions according to the present invention may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories, and sterile injectable solutions, respectively, according to conventional methods. Can be used.

Carriers, excipients and diluents that may be included in the compositions of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants are usually used.

Solid form preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid form preparations contain at least one excipient such as starch, calcium carbonate, sucrose ( It is prepared by mixing sucrose or lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.

Oral liquid preparations include suspending agents, liquid solutions, emulsions, and syrups, and may include various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate and the like can be used.

As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

Preferred dosages of the active ingredients of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art.

However, for the preferred effect, the active ingredient of the present invention is preferably administered at 0.0001 to 100 mg / kg, preferably 0.001 to 10 mg / kg per day. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.

The active ingredient of the present invention can be administered to mammals such as rats, mice, livestock, humans by various routes. All modes of administration can be expected, for example by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.

The present invention provides a dietary supplement for preventing and improving oxidation-related diseases containing saury fraction dry powder or extracts thereof.

The health functional food of the present invention is a tablet or capsule administered to the human body for the purpose of preventing a specific human disease, alleviating the symptoms thereof, or helping to treat a specific disease, as prescribed by the law (health functional food law). , Pills, liquids, and the like.

The present invention provides a dietary supplement or food additives containing saury fraction dry powder or extract thereof and food acceptable food additives having an effect of preventing and improving oxidation-related diseases.

Food acceptable acceptable food additives as defined herein include ingredients added in trace amounts to foods already known in the art, such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors, natural flavors, and the like. Flavors, coloring and neutralizing agents (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, carbonated drinks And carbonating agent.

The dietary supplement of the present invention includes forms such as health drinks, tablets, capsules, pills, liquids, and the like.

Examples of the food to which the active ingredient of the present invention can be added include various foods, beverages, gums, teas, vitamin complexes, and health functional foods.

It may also be added to food or beverages for the therapeutic and prophylactic purposes pursued by the present invention.

 Accordingly, the present invention also provides a saury fraction dry powder or a food additive containing the extract thereof having the effect of preventing and ameliorating oxidation-related diseases.

At this time, the amount of the active ingredient in the food or beverage is generally added to the dietary supplement composition of the present invention to 0.01 to 50% by weight, preferably 0.01 to 15% by weight of the total food weight, the health beverage composition is 100 It can be added at a ratio of 0.02 to 5 g, preferably 0.3 to 1 g, based on ml.

The health beverage composition of the present invention does not have any particular limitation except for containing the active ingredient as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates, etc. as additional ingredients, as in general beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose, for example polysaccharides such as maltose and sucrose, and conventional sugars such as dextrin and cyclodextrin. And sugar alcohols such as xylitol, sorbitol, and erythritol.

As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of such natural carbohydrates is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.

In addition, the dietary supplement or composition thereof of the present invention may contain a flesh for preparing natural fruit juice and fruit juice beverage and vegetable beverage. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected from the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.

The present invention relates to a composition for preventing and treating oxidation-related diseases containing saury fraction dry powder or extract thereof as an active ingredient. Specifically, saury fraction dry powder or extract thereof of the present invention is characterized in that the lipid lipid peroxide of hyperlipidemic rats It was confirmed that the antioxidant effect by reducing the active oxygen and showing the activity of SOD (superoxide dismutase), the composition can be usefully used as a pharmaceutical composition or health functional food for the prevention and treatment of oxidation-related diseases.

Hereinafter, the present invention will be described in detail by the following Examples and Experimental Examples.

However, the following Examples and Experimental Examples are only illustrative of the present invention, the contents of the present invention is not limited by the following Examples, Reference Examples and Experimental Examples.

Reference Example  1. Preparation of Experimental Materials

1-1. Selection of experimental animal model

The experimental animals were purchased from SPF Sprague Dawley (SD) rats and 20-25 g, 20-50 g ICR male rats from Biolink Co., Ltd. Only healthy animals exhibiting were used for the experiment. The breeding environment of this experiment was used in experimental animal breeding room (TECNIPLAST, Italy) of Kyungsung University Pharmacy set up with temperature 22 ± 3 ℃, relative humidity 50 ± 10%, lighting time 12 hours (07: 00 ~ 19: 00). Solid feed (Samyang feed, Daejeon) and negative water (water supply) were ingested freely. 24 hours before the experiment time only watering and fasting. At this time, the experimental animals were treated within a certain time (10:00 AM ~ 12:00 AM) in consideration of the daily variation of enzyme activity.

Example  1. Each part of saury Fraction  Produce

1-1. Saury Fraction Dry Powder

Saury ( Cololabis saira ) was harvested on the east coast in October 2007 with a body length of 29.5 ± 1.3 cm and body weight of 98.0 ± 19.4 g, and was provided frozen from Jumunjin strait of Gangneung-si. After thawing the frozen sample, the foreign material and salt were washed and divided into 4 fractions each of the whole body, flesh, internal organs, head + tail + bone of saury, and vacuum-dried (Vaccum Freeze Dryer, PVIFD30A, Korea Ilsan). crushed into a mesh and the entire body of saury (hereinafter referred to as C-1), flesh (hereinafter referred to as C-2), internal organs (hereinafter referred to as C-3), head + tail + bone (hereinafter referred to as C-4) ) Was used in the following experimental examples.

1-2. Fraction Extract of Saury

After mixing 500 g of each freeze-dried saury fraction obtained in 1-1 in 50 l of water, and heating the mixture at 100 ° C. for about 36 hours, the components contained in each saury dissolve, wherein free evaporation occurs. Open the top of the vessel to remove a significant amount of water by evaporation. Through the heating process, the flesh portion of the saury is dissolved in the liquid phase, and finally, a liquid extract having a high concentration and high viscosity is formed, and some solid components such as bones and residues remain as deposits at the bottom of the container. After the heating process, the extract was cooled to room temperature, filtered using a filter paper (3M), and the filtrate was concentrated under reduced pressure using a rotary pressure reducer (EYELA FDU-1100) to extract the whole body of saury (hereinafter 'CE-). 1 ') 35 g, flesh extract (hereinafter referred to as' CE-2') 35 g, visceral extract (hereinafter referred to as' CE-3 ') 35 g, head + tail + bone extract (hereinafter referred to as' CE-4') 35 g was obtained.

Experimental Example  Changes in Serum Lipid Components in Rats Inducing Dietary Hyperlipidemia

Induction of dietary hyperlipidemia was induced by raising 6 weeks of preparation animals with 1% cholesterol and 0.5% Na-cholic acid sodium salt (see Table 1).

                                                      (g / kg diet) ingredient Basic dietary Hyperlipidemia Diet Casein 200 200 ㎗-Methionine 3 3 Corn starch 150 150 Sucrose 500 345 Cellulose 50 50 Corn oil 50 - AIN-mineral Mixture ^{1 )} 35 35 AIN-vitamin Mixture ^{2 )} 10 10 Choline bitartate 2 2 Beef tallow - 205 Fat (%) 11.7 40.0 1) Mineral mixture based on the pattern of Rogers and Haper (1965) contain the following (g / kg diet): calcium phosphate dibasic 500.0, sodium chloride 74.0, potassium citrate monohydrate 220.0, potassium sulfate 52.0, magnesium oxide 24.0, magnesium carbonate 3.5 , ferric citrate 6.0, zinc carbonate 1.6, cupuric carbonate 0.3, potassium iodate 0.01, chromium potassium sulfate 0.55, sucrose, finely powered make 1,000 2) Vitamin mixture (g / kg diet): thiamine HCl 0.6, biotin 0.02, riboflavin 0.6, cyanocobalamine 0.001, pyridoxine HCl 0.7, retinyl acetate 0.8, nicotinic acid 3.0, ㎗-tocopherol 3.8, Ca-pantothenate 1.6, 7-dehydrocholesterol 0.0025, folic acid 0.2, methionine 0.005, sucrose, finely powered make 1,000

Thereafter, the dried powder and extract of each fraction of saury obtained in the above example was dissolved in 10% Tween 80, diluted with physiological saline, and each sample 100 or 200 mg / kg was orally administered to the experimental animals for 4 weeks. Administered. The control group used the same amount of the above solvent. After the sample was injected, the animal was lightly anesthetized with CO ₂ , blood was collected from the abdominal aorta, left for 30 minutes, centrifuged at 3,000 rpm for 10 minutes, and serum was separated from the separated serum. And the content of phospholipids (Lee Yeon-sil, et al., Effects of Extracts of Seaweed Moxibustion on Lipid Metabolism, Journal of Biochemistry, 35 (2) , pp.143-146, 2004).

In order to determine the total lipid content in blood, the following experiments were conducted using the method described in the literature (Frings, CS et al, A colorimetric method for determination of total serum lipids based on the sulfophosphovanillin reaction, Am. J. Clin. Path. , 53 , pp. 89-92, 1970). For the measurement of total lipid content in blood, 10 ml of sample and 2 ml of c-H2SO4 were left in a 95 ° C water bath for 10 minutes, 0.1 ml of the mixed solution was added, and incubated at 37 ° C for 15 minutes with phospho-vanillin reagent. Absorbance was measured at nm.

In order to determine the content of blood phospholipids, it was measured according to the method described in the existing literature (Chen, PS et al., Micro determination of phosphorus. Anal. Chem. , 28 , pp. 1756-1760, 1956). Experiments were carried out using a kit (Iatron Chem. Co., Japan) prepared by the enzyme method of Chen et al. In other words, the enzyme reagent (containing phospholipase 3.9 U, choline oxidase 5.6 U, peroxidase 3.6 U, 4-aminoantipyrine 0.3252 mg) was dissolved in an enzyme reagent solution [containing tris (hydroxy-methyl) -aminomethane 6.057 mg] in an ice-cold phase. To 20 µl, 3.0 ml of the prepared enzyme solution was added. Thereafter, the mixture was left at 37 ° C. for 20 minutes, and the absorbance was measured at a wavelength of 500 nm using the reagent blank as a control. The content was expressed in mg / ㎎ according to a standard calibration curve.

To determine the content of triglycerides in blood, experiments were conducted according to the methods described in the literature (McGowan, MW et al., A peroxidase-coupled method for the colorimetric determination of serum triglycerides, Clin. Chem. , 29 , pp.538- 542, 1983). Experiments were performed using a kit (AM 157S-K, Asan) prepared by McGowan et al. In other words, the enzyme reagent (containing lipoprotein lipase 10,800 U, glycerol kinase 5.4 U, peroxidase 135,000 U, L-α-glycero phosphooxidase 160 U) on ice-cooled solution [N, N-bis (2-hydroxyethyl) -2- containing 0.427 g / dl of aminomethane sulfonic acid] and 3.0 ml of the prepared enzyme solution was added to 20 µl of the sample. After incubation at 37 ℃ for 10 minutes, the absorbance was measured at a wavelength of 550 nm using the reagent blank as a control, and the blood content was expressed in mg / 준 according to the standard calibration curve.

As a result, as shown in Table 2, the total lipid level in the blood was 468.2 mg / dL in the experimental group administered with 100 mg / kg saury fraction compared to the control group 498.5 mg / dL, but 200 mg / kg administration. In one experimental group, it was significantly reduced to 425.8 mg / dl. On the other hand, blood phospholipid content was 128.7 mg / dL and 121.5 mg / dL in the experimental group treated with 100 and 200 mg / kg saury fractions, respectively, compared to 147.6 mg / dL. However, the triglyceride level in blood was significantly reduced to 18.29 mg / dL and 161.4 mg / dL in the experimental group administered 100 and 200 mg / kg of saury fractions, respectively, compared to 200.7 mg / dL.

Therefore, the experimental group treated with saury fraction showed a decrease in the total lipid and triglyceride contents compared to the control group, but did not affect the concentration of phospholipids with antioxidant effects.

Treatment group Concentration (mg / kg) Total lipid Phospholipids Triglyceride mg / ㎗ Normal 286.2 ± 23.5 ^c 119.8 ± 15.8 ^a 87.9 ± 9.21 ^d Control 498.5 ± 37.8 ^a 147.6 ± 16.4 ^a 200.7 ± 6.25 ^a C-2 (years old) 100 200 468.2 ± 19.4 ^ab 425.8 ± 23.9 ^b 128.7 ± 10.5 ^a 121.5 ± 14.2 ^a 182.9 ± 7.36 ^b 161.4 ± 5.43 ^c Rats were treated saury meat daily for consecutive four weeks of orally administration on hyperlipidemic state animal, and killed 24hr after the last treatment of fraction. The assay procedure was described in the experimental methods. Values are mean ± S.D. for six experiments. Values followed by the same letter are not significantly different (p <0.05).

Experimental Example  2. Effect of Dietary Hyperlipidemia on Blood Lipid Peroxidation and Free Oxygen in Rats

In the rat induced dietary hyperlipidemia as in Experimental Example 1, the saury fraction obtained in Example was orally administered to an experimental animal as in Experimental Example 1, and serum was isolated as in Experimental Example 1, The effects on lipid peroxidation and free radicals were examined.

To determine the content of lipid peroxide (LPO) in the blood

Measurements were made according to methods described in the literature (Yagi, K. Lipid peroxides and human diseases. Chemistry and Physics of Lipids , 45 , pp. 337-342, 1987). In accordance with the method of Yagi, add 4.0 ml of 1 / 12N H ₂ SO ₄ to 20 µl of serum, add 0.5 ml of 10% phosphotungstic acid, and leave at room temperature for 5 minutes, then centrifuge to take only precipitated serum protein. Then, 2.0 ml of 1 / 12N H ₂ SO ₄ and 0.3 ml of 10% phosphotungstic acid were added thereto, followed by centrifugation. Thereafter, only the precipitate was taken and 1.0 ml of a solution of 4.0 ml of distilled water, a mixture of 0.67% thiobarbituric acid and acetic acid 1: 1 was added thereto, and the mixture was reacted at 95 ° C. for 60 minutes. After centrifugation at 15 minutes, the resulting red n-BuOH was taken and absorbance was measured using a spectrofluorometer (Jasco, V-600, Japan) (Ex: 515 nm, Em: 553 nm). Tetraethoxypropane 0.5 nM was reacted with the standard solution in the same manner to measure the absorbance and to calculate the blood LPO content by the following equation (1).

[Equation 1]

LPO in blood = (absorbance of test solution / absorbance of standard solution) × 25 (nmole / ml serum)

Blood free radicals (Hydroxy radical) content was determined according to the method described in the literature in order to measure (Kobatake, Y. et al., Influence of fish consumption on serum lipid and lipid peroxide concentrations mid㎗e in aged subjects. J. Japan Soc.Nutr. & Food Sci., 40 , pp.103-110, 1987) 0.54 M NaCl, 0.1 M potassium phosphate buffer (pH 7.4), 10 mM in 34.8 μl serum according to the method of Kobatake et al. NaN3, 7 mM deoxyribose, 5 mM ferrous ammonium sulfate and distilled water were added to 333.3 μl, mixed well in a vortex, and allowed to stand at 37 ° C. for 15 minutes. Here, 67 μl of serum was added, and 5 μl of 8.1% sodium dodecyl sulfate 7, 500 μl of 20% acetic acid and 25 μl of distilled water were mixed. Then, 333 μl of 1.2% thiobarbituric acid was added to the thermostat (100 ° C) Heated for 30 minutes and then cooled to room temperature. Then, the absorbance was measured at a wavelength of 532 nm of the supernatant obtained by centrifugation at 700 × g for 5 minutes, and the content was expressed as nmole / mg protein according to a standard calibration curve.

The content of the serum SOD (superoxide dismutase) was measured according to the method described in the literature in order to measure (Oyanagui, Y. Reevaluation of assay methods and establishment of kit for superoxide dismutase activity. Anal. Biochem., 42, pp.290- 295, 1984). Dilute the serum 100-fold with potassium phosphate buffer according to the method of Oyanagui, and put 100 μl of this into the test tube. 500 μl of distilled water, 200 μl of reagent A (3 mM hydroxylamine / 3 mM hypoxanthine) and reagent B [ 7.5 mU / mL xanthine oxidase (XO) with 0.1 mM EDTA-2Na] was added thereto, mixed well in a vortex, and allowed to stand for 40 minutes in a 37 ° C thermostat. 2.0 ml of Reagent C (300 mg of sulfanilic acid / 5.0 mg N-1-naphthyl-ethylenediamine in 500 ml of 16.7% acetic acid) was added to the reaction mixture, mixed well and allowed to stand at room temperature for 20 minutes, followed by absorbance at 550 nm. The SOD activity in blood was measured according to the standard calibration curve.

As a result, as shown in Table 3, the blood lipid peroxide content of the control group was 12.4 nmole / ml, 1.7 times higher than that of the normal group, 7.2 nmole / ml. In addition, free radicals in blood increased 2.5 times in the control group compared to the normal group. However, oral administration of saury fractions showed no significant decrease, but the numbers decreased. On the other hand, the effect on SOD activity was 2.00 μ / mL in the experimental group compared to 3.96 μ / mL in the normal group, and 49% of the saury fractions did not reach the normal level. Increased to 2.38 μ / mL and 2.65 μ / mL, respectively.

Therefore, the oral administration of saury fractions reduced the amount of lipid peroxidation and free radicals, and the amount of free radicals was significantly increased. This suggests that saury fraction is effective in preventing oxidation-related diseases.

Treatment group Concentration (mg / kg) LPO (MDA nmole / ml) Free radicals (nmole / mg protein) SOD (μ / ml) Normal group 7.2 ± 1.20 ^b 2.51 ± 0.97 ^b 3.96 ± 0.20 ^a Control 12.4 ± 2.59 ^a 6.48 ± 1.19 ^a 2.00 ± 0.40 ^c C-2 (years old) 100 200 12.0 ± 1.46 ^a 10.6 ± 1.30 ^a 6.23 ± 1.10 ^a 5.33 ± 0.80 ^a 2.38 ± 0.37 ^bc 2.65 ± 0.25 ^b Values are represent mean ± SD (n = 6). Values sharing the same superscript letter are not significantly different each other (p <0.05) by Duncan ^, s multiple range test.

Claims (6)

A saury fraction dried powder or a pharmaceutical composition for the prevention and treatment of oxidation-related diseases containing the extract as an active ingredient. The saury fraction of claim 1, wherein the saury fraction is fractionated from at least one selected from the group consisting of the entire torso, flesh, intestine, head, fin, bone, tail, cartilage, shell, muscle, eye and gill of the saury. Pharmaceutical composition. The method of claim 1, wherein the oxidation-related disease includes one or more diseases selected from the group consisting of cancer, diabetes, hepatitis, gastritis, nephritis, heart infection, rheumatoid arthritis, heart disease, acquired immunodeficiency syndrome, cataract, and skin tumor. Pharmaceutical composition characterized in that. Pharmaceutical composition of the saury fraction dry powder or extract thereof is 0.1 to 50% by weight based on the total weight. Saury Fraction A dietary supplement for the prevention and improvement of oxidation-related diseases containing dry powder or extract thereof as an active ingredient. The dietary supplement according to claim 5, which is a tablet, capsule, pill or liquid.